578 related articles for article (PubMed ID: 33648511)
21. A novel immune checkpoint score system for prognostic evaluation in pancreatic adenocarcinoma.
Chen Y; Lin X; Zou X; Qian Y; Liu Y; Wang R; Wang X; Yu X; Liu C; Cheng H
BMC Gastroenterol; 2023 Apr; 23(1):113. PubMed ID: 37024802
[TBL] [Abstract][Full Text] [Related]
22. Quantification of m6A RNA methylation modulators pattern was a potential biomarker for prognosis and associated with tumor immune microenvironment of pancreatic adenocarcinoma.
Wang L; Zhang S; Li H; Xu Y; Wu Q; Shen J; Li T; Xu Y
BMC Cancer; 2021 Jul; 21(1):876. PubMed ID: 34332578
[TBL] [Abstract][Full Text] [Related]
23. Screening of Tumor Antigens and Construction of Immune Subtypes for mRNA Vaccine Development in Head and Neck Squamous Cell Carcinoma.
Li HX; Liu TR; Tu ZX; Xie CB; Wen WP; Sun W
Biomolecules; 2022 Dec; 13(1):. PubMed ID: 36671475
[TBL] [Abstract][Full Text] [Related]
24. Development and Validation of an Inflammatory Response-Related Gene Signature for Predicting the Prognosis of Pancreatic Adenocarcinoma.
Deng ZL; Zhou DZ; Cao SJ; Li Q; Zhang JF; Xie H
Inflammation; 2022 Aug; 45(4):1732-1751. PubMed ID: 35322324
[TBL] [Abstract][Full Text] [Related]
25. Identification of Neoantigens and Construction of Immune Subtypes in Prostate Adenocarcinoma.
Gao Y; Wang G; Chen Y; Zhang M; Gao W; Shang Z; Niu Y
Front Genet; 2022; 13():886983. PubMed ID: 35547260
[No Abstract] [Full Text] [Related]
26. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
Front Genet; 2022; 13():853113. PubMed ID: 35734437
[No Abstract] [Full Text] [Related]
27. Exploring the significance of novel immune-related gene signatures in the prognosis and immune features of pancreatic adenocarcinoma.
Chen B; Hu C; Jiang L; Xiang Z; Zuo Z; Lin Y; Liu C
Int Immunopharmacol; 2021 Mar; 92():107359. PubMed ID: 33465729
[TBL] [Abstract][Full Text] [Related]
28. Bioinformatics analysis identified MMP14 and COL12A1 as immune-related biomarkers associated with pancreatic adenocarcinoma prognosis.
Li Y; Su Z; Wei B; Qin M; Liang Z
Math Biosci Eng; 2021 Jun; 18(5):5921-5942. PubMed ID: 34517516
[TBL] [Abstract][Full Text] [Related]
29. Discovering a Four-Gene Prognostic Model Based on Single-Cell Data and Gene Expression Data of Pancreatic Adenocarcinoma.
Huang W; Li J; Zhou S; Li Y; Yuan X
Front Endocrinol (Lausanne); 2022; 13():883548. PubMed ID: 35800432
[TBL] [Abstract][Full Text] [Related]
30. Integrated bioinformatics analysis identified COL11A1 as an immune infiltrates correlated prognosticator in pancreatic adenocarcinoma.
Zheng X; Liu X; Zheng H; Wang H; Hong D
Int Immunopharmacol; 2021 Jan; 90():106982. PubMed ID: 33129696
[TBL] [Abstract][Full Text] [Related]
31. A prospective prognostic signature for pancreatic adenocarcinoma based on ubiquitination-related mRNA-lncRNA with experimental validation in vitro and vivo.
Wang Z; Yuan Q; Chen X; Luo F; Shi X; Guo F; Ren J; Li S; Shang D
Funct Integr Genomics; 2023 Aug; 23(3):263. PubMed ID: 37540295
[TBL] [Abstract][Full Text] [Related]
32. Tumor antigens and immune subtypes of glioblastoma: the fundamentals of mRNA vaccine and individualized immunotherapy development.
Wu C; Qin C; Long W; Wang X; Xiao K; Liu Q
J Big Data; 2022; 9(1):92. PubMed ID: 35855914
[TBL] [Abstract][Full Text] [Related]
33. CHST12: a potential prognostic biomarker related to the immunotherapy response in pancreatic adenocarcinoma.
Liu K; Li L; Han G
Front Endocrinol (Lausanne); 2023; 14():1226547. PubMed ID: 38333724
[TBL] [Abstract][Full Text] [Related]
34. Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.
Ping H; Yu W; Gong X; Tong X; Lin C; Chen Z; Cai C; Guo K; Ke H
Invest New Drugs; 2022 Dec; 40(6):1173-1184. PubMed ID: 35962880
[TBL] [Abstract][Full Text] [Related]
35. Discovering ferroptosis-associated tumor antigens and ferroptosis subtypes in pancreatic adenocarcinoma to facilitate mRNA vaccine development.
Yan T; Wang L
Heliyon; 2024 Mar; 10(5):e27194. PubMed ID: 38463885
[TBL] [Abstract][Full Text] [Related]
36. Identification of tumour immune microenvironment-related alternative splicing events for the prognostication of pancreatic adenocarcinoma.
Chen B; Deng T; Deng L; Yu H; He B; Chen K; Zheng C; Wang D; Wang Y; Chen G
BMC Cancer; 2021 Nov; 21(1):1211. PubMed ID: 34772375
[TBL] [Abstract][Full Text] [Related]
37. Crosstalk of ferroptosis regulators and tumor immunity in pancreatic adenocarcinoma: novel perspective to mRNA vaccines and personalized immunotherapy.
Shi Y; Wang Y; Dong H; Niu K; Zhang W; Feng K; Yang R; Zhang Y
Apoptosis; 2023 Oct; 28(9-10):1423-1435. PubMed ID: 37369808
[TBL] [Abstract][Full Text] [Related]
38. Discovery of lung adenocarcinoma tumor antigens and ferroptosis subtypes for developing mRNA vaccines.
Chen Y; Zhang C; Li Y; Tan X; Li W; Tan S; Liu G
Sci Rep; 2024 Feb; 14(1):3219. PubMed ID: 38331967
[TBL] [Abstract][Full Text] [Related]
39. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.
Xu H; Zheng X; Zhang S; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):159. PubMed ID: 34872567
[TBL] [Abstract][Full Text] [Related]
40. Identify potential prognostic indicators and tumor-infiltrating immune cells in pancreatic adenocarcinoma.
Shi T; Gao G
Biosci Rep; 2022 Feb; 42(2):. PubMed ID: 35083488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]